ES2532361T3 - CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias - Google Patents

CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias Download PDF

Info

Publication number
ES2532361T3
ES2532361T3 ES12002502.8T ES12002502T ES2532361T3 ES 2532361 T3 ES2532361 T3 ES 2532361T3 ES 12002502 T ES12002502 T ES 12002502T ES 2532361 T3 ES2532361 T3 ES 2532361T3
Authority
ES
Spain
Prior art keywords
disease
activity
efficacy
therapy
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12002502.8T
Other languages
English (en)
Spanish (es)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ES2532361T3 publication Critical patent/ES2532361T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
ES12002502.8T 2007-10-24 2008-10-15 CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias Active ES2532361T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin

Publications (1)

Publication Number Publication Date
ES2532361T3 true ES2532361T3 (es) 2015-03-26

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12002502.8T Active ES2532361T3 (es) 2007-10-24 2008-10-15 CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias
ES08842581T Active ES2389751T3 (es) 2007-10-24 2008-10-15 Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08842581T Active ES2389751T3 (es) 2007-10-24 2008-10-15 Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2532361T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2201376E (https=)
SI (2) SI2201376T1 (https=)
WO (1) WO2009053523A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228970A1 (en) * 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
US20030099608A1 (en) * 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
PL2503338T3 (pl) 2015-06-30
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
CA2702635A1 (en) 2009-04-30
PT2503338E (pt) 2015-03-05
JP2012159514A (ja) 2012-08-23
SI2503338T1 (sl) 2015-06-30
CY1116089T1 (el) 2017-02-08
FI20070795A0 (fi) 2007-10-24
JP4982610B2 (ja) 2012-07-25
HRP20150181T1 (hr) 2015-06-19
DK2503338T3 (en) 2015-03-09
CY1113403T1 (el) 2016-06-22
US20100209942A1 (en) 2010-08-19
KR20100059902A (ko) 2010-06-04
KR20160029869A (ko) 2016-03-15
ES2389751T3 (es) 2012-10-31
EP2503338A2 (en) 2012-09-26
PL2201376T3 (pl) 2013-01-31
WO2009053523A1 (en) 2009-04-30
EP2201376A4 (en) 2011-03-23
EP2201376B1 (en) 2012-08-08
JP5619810B2 (ja) 2014-11-05
PT2201376E (pt) 2012-08-20
DK2201376T3 (da) 2012-10-15

Similar Documents

Publication Publication Date Title
ES2532361T3 (es) CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias
Hartmann et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein
Mukama et al. A highly sensitive and specific lateral flow aptasensor for the detection of human osteopontin
ES2718731T3 (es) Métodos, dispositivos y kits para detectar o monitorizar la lesión renal aguda
Muniyappa et al. Role of insulin resistance in endothelial dysfunction
Léguillette et al. Myosin, transgelin, and myosin light chain kinase: expression and function in asthma
ES2472791T3 (es) Polip�ptidos natriur�ticos
Hart et al. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury
US20150355180A1 (en) Differential Expression of Novel Protein Markers for the Diagnosis and Treatment of Eosinophilic Esophagitis
US20130217033A1 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
ES2911270T3 (es) Composición para diagnosticar enfermedades infecciosas o complicaciones infecciosas mediante el uso de triptofanil-arnt sintetasa y método para detectar el marcador de diagnóstico
Cibor et al. Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease.
Covarrubias-Zambrano et al. Optical biosensing of markers of mucosal inflammation
Engebretsen et al. Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats
Chakraborty et al. Neutrophil gelatinase associated lipocalin: structure, function and role in human pathogenesis
Mielczarek-Palacz et al. Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2–markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics
Kozina et al. The Effect of High-Salt Diet on Oxidative Stress Production and Vascular Function in Tff3−/−/C57BL/6N Knockout and Wild Type (C57BL/6N) Mice
Alver et al. Malondialdehyde and CA II autoantibody levels are elevated in children with undescended testes
Lewandowska-Polak et al. 2 Lack of Association Between Aspirin-Triggered 15-Hydroxyeicosatetraenoic Acid Release and Mast Cell/Eosinophil Activation in Nasal Polyps From Aspirin-Sensitive Patients
ES2697299B2 (es) Biomarcadores diferenciales de asma
Sandström et al. Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
ES2217931B1 (es) Metodo de diagnostico de la evolucion de la masa intestinal absortiva en un individuo.
Rangel-López et al. Plasma endothelin-1 and circulating endothelial progenitor cell levels after cardiopulmonary bypass in children with congenital heart diseases: a preliminary study
Kayani et al. Aortoenteric fistula as shown by multidetector computed tomography
Mera et al. Serum profile of IL-6, TNF-α, IL-12 and IFN-γ in early sepsis